The Journal of Neuroscience, June 11, 2008, 28(24):6231-6238; doi:10.1523/JNEUROSCI.0504-08.2008
Previous Article | Next Article 
Cellular/Molecular
TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons
Ning Qin,
Michael P. Neeper,
Yi Liu,
Tasha L. Hutchinson,
Mary Lou Lubin, and
Christopher M. Flores
Analgesics Team, East Coast Research and Early Development, Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania 19477-0776
Correspondence should be addressed to Dr. Ning Qin, Analgesics Team, East Coast Research and Early Development, Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, P.O. Box 776, Spring House, PA 19477-0776. Email: nqin{at}prdus.jnj.com
Transient receptor potential V2 (TRPV2) has been proposed to be a high-threshold thermosensor. However, further elucidation of the channel properties and physiological role of TRPV2 have been hindered by the lack of selective pharmacological tools as well as by the species-dependent differences in the activation of this channel. In the present study, we have used cell-based calcium mobilization and electrophysiological assays to identify and characterize several novel cannabinoid TRPV2 agonists. Among these, cannabidiol was found to be the most robust and potent (EC50 = 3.7 µM), followed by
9-tetrahydrocannabinol (EC50 = 14 µM) and cannabinol (EC50 = 77.7 µM). We also demonstrated that cannabidiol evoked a concentration-dependent release of calcitonin gene-related peptide (CGRP) from cultured rat dorsal root ganglion neurons in a cannabinoid receptor- and TRPV1-independent manner. Moreover, the cannabidiol-evoked CGRP release depended on extracellular calcium and was blocked by the nonselective TRP channel blocker, ruthenium red. We further provide evidence through the use of small interfering RNA knockdown and repetitive stimulation studies, to show that cannabidiol-evoked CGRP release is mediated, at least in part, by TRPV2. Together, these data suggest not only that TRPV2 may comprise a mechanism whereby cannabidiol exerts its clinically beneficial effects in vivo, but also that TRPV2 may constitute a viable, new drug target.
Key words: TRPV2; cannabidiol; dorsal root ganglion; pain; agonist; CGRP release
Received July 9, 2007;
revised April 28, 2008;
accepted April 30, 2008.
Correspondence should be addressed to Dr. Ning Qin, Analgesics Team, East Coast Research and Early Development, Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, P.O. Box 776, Spring House, PA 19477-0776. Email: nqin{at}prdus.jnj.com
This article has been cited by other articles:

|
 |

|
 |
 
Y. Ren, J. Whittard, A. Higuera-Matas, C. V. Morris, and Y. L. Hurd
Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances
J. Neurosci.,
November 25, 2009;
29(47):
14764 - 14769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Vriens, G. Appendino, and B. Nilius
Pharmacology of Vanilloid Transient Receptor Potential Cation Channels
Mol. Pharmacol.,
June 1, 2009;
75(6):
1262 - 1279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Iliff, R. Wang, D. C. Zeldin, and N. J. Alkayed
Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels
Am J Physiol Heart Circ Physiol,
May 1, 2009;
296(5):
H1352 - H1363.
[Abstract]
[Full Text]
[PDF]
|
 |
|